Anzeige
Mehr »
Samstag, 14.02.2026 - Börsentäglich über 12.000 News
20 Mio. € Bewertung. Zwei zugelassene Psychedelika-Produkte. NASDAQ-Uplist in Arbeit.
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
273 Leser
Artikel bewerten:
(0)

Global Cardiac Rhythm Management (CRM) Devices Market 2017-2021 - Key Vendors are Abbott, Boston Scientific & Medtronic

DUBLIN, October 30, 2017 /PRNewswire/ --

The "Global Cardiac Rhythm Management (CRM) Devices Market 2017-2021" report has been added to Research and Markets' offering.

Research and Markets Logo

The global cardiac rhythm management (CRM) devices market to grow at a CAGR of 7.64% during the period 2017-2021.

Global Cardiac Rhythm Management (CRM) Devices Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market. To calculate the market size, the report considers the total sales volume and the revenue generated from it.

The latest trend gaining momentum in the market is Technological advances. There have been several advancements in the CRM devices. The ICD has seen advancement in the battery life. There have been improvements in patient monitoring to avoid needless shocks, the introduction of quadripolar lead devices to improve device programming and to improve therapy efficacy, and development of magnetic resonance imaging (MRI)-safe ICDs. The newer ICDs have been offering pacing functions and the devices are now integrated with wireless remote monitoring, without having the patient to visit the clinic on a regular basis.

According to the report, one of the major drivers for this market is Rising incidence of CVDs. The increasing burden of vascular diseases such as CADs, PADs, CVDs, and neurovascular diseases will increase the patient pool. Factors such as diabetes, aging population, obesity, and hypertension are the major factors leading to vascular diseases. The increasing prevalence of cardiac disorders will lead to higher demand for CRM devices.

Further, the report states that one of the major factors hindering the growth of this market is Dearth of skilled healthcare professionals. CVDs are the leading cause of mortality in the world. The cardiovascular segment has seen much advancement in the recent years, but the shortage of cardiovascular (CV) workforce has become the subject of intense scrutiny in recent years. Forecasters predict a higher shortage of cardiologist in the future. The growing burden of CVD is the most significant factor influencing the demand of cardiologists. According to NCBI, CVD accounts for more than 17.3 million deaths globally per year. It is projected that by 2030, over 40% of the US population is projected to have CVD.

Key vendors

  • Abbott
  • Boston Scientific
  • Medtronic

Other prominent vendors

  • BIOTRONIK
  • Cardiac Science
  • CCC Medical Devices (acquired by Greatbatch)
  • Cook Medical
  • GE Healthcare
  • Integer
  • Mortara Instrument (acquired by Hill-Rom Holdings)
  • Neovasc
  • Philips Healthcare
  • Physio-Control (Subsidiary of Stryker)
  • Rchling Medical
  • Schiller
  • LivaNova
  • ZOLL Medical

Key Topics Covered:

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: RESEARCH METHODOLOGY

PART 04: INTRODUCTION

  • Market outline

PART 05: MARKET LANDSCAPE

  • Market overview
  • Market size and forecast
  • Five forces analysis

PART 06: MARKET SEGMENTATION BY PRODUCT

  • Segmentation by product
  • Comparison by product
  • Defibrillators - market size & forecast
  • Pacemakers - market size & forecast
  • CRT devices - market size & forecast
  • Market opportunity by product

PART 07: MARKET SEGMENTATION BY END-USER

  • Hospitals
  • ASCs
  • Physicians' clinics

PART 08: REGIONAL LANDSCAPE

  • Geographical segmentation
  • Regional comparison
  • Americas - market size & forecast
  • EMEA - market size & forecast
  • APAC - market size & forecast
  • Market opportunity

PART 09: DECISION FRAMEWORK

  • Market drivers
  • Market challenges

PART 10: MARKET TRENDS

PART 11: VENDOR LANDSCAPE

  • Competitive scenario
  • Other prominent vendors

PART 12: VENDOR ANALYSIS

  • Vendor overview
  • Abbott
  • Boston Scientific
  • Medtronic

PART 13: APPENDIX

For more information about this report visit https://www.researchandmarkets.com/research/3d7fz2/global_cardiac

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

© 2017 PR Newswire
Favoritenwechsel - diese 5 Werte sollten Anleger im Depot haben!
Das Börsenjahr 2026 ist für viele Anleger ernüchternd gestartet. Tech-Werte straucheln, der Nasdaq 100 tritt auf der Stelle und ausgerechnet alte Favoriten wie Microsoft und SAP rutschen zweistellig ab. KI ist plötzlich kein Rückenwind mehr, sondern ein Belastungsfaktor, weil Investoren beginnen, die finanzielle Nachhaltigkeit zu hinterfragen.

Gleichzeitig vollzieht sich an der Wall Street ein lautloser Favoritenwechsel. Während viele auf Wachstum setzen, feiern Value-Titel mit verlässlichen Cashflows ihr Comeback: Telekommunikation, Industrie, Energie, Pharma – die „Cashmaschinen“ der Realwirtschaft verdrängen hoch bewertete Hoffnungsträger.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau in dieses neue Marktbild passen: solide, günstig bewertet und mit attraktiver Dividende. Werte, die nicht nur laufende Erträge liefern, sondern auch bei Marktkorrekturen Sicherheit bieten.

Jetzt den kostenlosen Report sichern – bevor der Value-Zug 2026 endgültig abfährt!

Dieses exklusive PDF ist nur für kurze Zeit gratis verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.